191 related articles for article (PubMed ID: 26977877)
1. Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down.
Hobbs GA; Wittinghofer A; Der CJ
Cancer Cell; 2016 Mar; 29(3):251-253. PubMed ID: 26977877
[TBL] [Abstract][Full Text] [Related]
2. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Lito P; Solomon M; Li LS; Hansen R; Rosen N
Science; 2016 Feb; 351(6273):604-8. PubMed ID: 26841430
[TBL] [Abstract][Full Text] [Related]
3. Design of Small Molecules That Compete with Nucleotide Binding to an Engineered Oncogenic KRAS Allele.
Zhang Y; Larraufie MH; Musavi L; Akkiraju H; Brown LM; Stockwell BR
Biochemistry; 2018 Feb; 57(8):1380-1389. PubMed ID: 29313669
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
5. KRAS
Cagir A; Azmi AS
Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
[No Abstract] [Full Text] [Related]
6. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS.
Li C; Vides A; Kim D; Xue JY; Zhao Y; Lito P
Science; 2021 Oct; 374(6564):197-201. PubMed ID: 34618566
[TBL] [Abstract][Full Text] [Related]
7. Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by
Sharma AK; Pei J; Yang Y; Dyba M; Smith B; Rabara D; Larsen EK; Lightstone FC; Esposito D; Stephen AG; Wang B; Beltran PJ; Wallace E; Nissley DV; McCormick F; Maciag AE
J Biol Chem; 2024 Feb; 300(2):105650. PubMed ID: 38237681
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
9. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
10. NMR
Sharma AK; Lee SJ; Rigby AC; Townson SA
Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
[TBL] [Abstract][Full Text] [Related]
11. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
12. In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis.
Gerber M; Goel S; Maitra R
Comput Biol Med; 2022 Feb; 141():105110. PubMed ID: 34920161
[TBL] [Abstract][Full Text] [Related]
13. Two Distinct Structures of Membrane-Associated Homodimers of GTP- and GDP-Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement.
Lee KY; Fang Z; Enomoto M; Gasmi-Seabrook G; Zheng L; Koide S; Ikura M; Marshall CB
Angew Chem Int Ed Engl; 2020 Jun; 59(27):11037-11045. PubMed ID: 32227412
[TBL] [Abstract][Full Text] [Related]
14. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
Zhao H; Li L; Liu J; Mai R; Chen J; Chen J
Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284
[TBL] [Abstract][Full Text] [Related]
15. Optical Control of the GTP Affinity of K-Ras(G12C) by a Photoswitchable Inhibitor.
Ge Z; Yang Z; Liang J; Dong D; Zhu M
Chembiochem; 2019 Dec; 20(23):2916-2920. PubMed ID: 31219673
[TBL] [Abstract][Full Text] [Related]
16. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
17. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.
Meng L; Chan EW; Ng C; Aimi J; Tran JC; Oh AJ; Merchant M; Purkey HE; Heffron TP; Kaur S; Xu K; Shi Z; He J
Anal Chem; 2022 Sep; 94(37):12927-12933. PubMed ID: 36083155
[No Abstract] [Full Text] [Related]
18. Hitting KRAS When It's Down.
Gabizon R; London N
J Med Chem; 2020 Jul; 63(13):6677-6678. PubMed ID: 32568546
[TBL] [Abstract][Full Text] [Related]
19. Signalling: Putting the brakes on KRAS-G12C nucleotide cycling.
Shipman L
Nat Rev Cancer; 2016 Mar; 16(3):127. PubMed ID: 26893067
[No Abstract] [Full Text] [Related]
20. Alternate mechanisms of ras activation are complementary and favor and formation of ras-GTP.
Patel G; MacDonald MJ; Khosravi-Far R; Hisaka MM; Der CJ
Oncogene; 1992 Feb; 7(2):283-8. PubMed ID: 1549350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
